Connect with us

News

Quick return of investment
Eli Lilly’s acquisition of Loxo Oncology

Published

on


News, Pharmaceuticals

Eli Lilly’s acquisition of Loxo Oncology marks the second multibillion-dollar deal in 2019 following the recent BMS and Celgene merger.

“Eli Lilly’s choice of Loxo is highly strategic due to Loxo’s unique oncology portfolio as well as its potential for quick return of investment. To this end, Lilly will immediately collect sales revenues from Loxo’s recently branded first-in-class tropomyosin receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib).

Vitrakvi’s strength comes from its first-to-market advantage, as well as its label, as it is approved based on the presence of a biomarker, neurotropic receptor tyrosine kinase (NTRK) fusion in tumors rather than location of the tumor. This means that the drug can be readily used in more than 17 different types of advanced cancers that are driven by NTRK fusions.

Loxo’s follow up second generation TRK inhibitor, LOXO-195, is designed to address the potential acquired resistance that could emerge in patients receiving Vitrakvi. The two agents will therefore allow Lilly to dominate the treatment paradigm in NTRK fusion driven cancers.

A second gem in Loxo’s clinical pipeline is LOXO-292, an inhibitor of rearranged during transfection (RET) kinase. Already granted a breakthrough therapy designation in RET-fusion positive NSCLC and RET–mutation positive medullary thyroid cancer, LOXO-292 will soon be Lilly’s second brand inherited from Loxo. Similar to Vitrakvi, LOXO-292 is first in its class and is expected to become the first branded RET inhibitor.

Ultimately, the deal will help Lilly replenish and diversify its oncology portfolio, which is losing ground due to the impending patent expiration and increasing market competition facing its leading oncology brands Alimta, Cyramza, and Verzenio.”

Volkan Gunduz, PhD, Senior Oncology and Hematology Analyst at GlobalData

Measurement, Instrumentation, Control & Automation News

287 patents in 2018
Patent portfolio expands further

Published

on

Consolidated innovation spirit: At its annual Innovators’ Meeting in Saint-Louis, France, Endress+Hauser honored the company’s inventors. Picture: Endress+Hauser
Consolidated innovation spirit: At its annual Innovators’ Meeting in Saint-Louis, France, Endress+Hauser honored the company’s inventors. (Picture: Endress+Hauser)

The number of patents submitted by the Endress+Hauser Group continues to rise. As reported during the annual Innovators’ Meeting held this year in France, the Group submitted 287 initial patents in 2018, a new record. Endress+Hauser owns nearly 7,800 active intellectual property rights worldwide.

“This year we once again achieved a record number of innovations, both in the number of patent filings and the number of approved patents.”

Angelika Andres, Corporate Director, Intellectual Property Rights at Endress+Hauser

While the 309 invention disclosures are a sign of the company’s ongoing innovation capability, the 537 granted patent applications also represent an all-time high.

Roughly one-third of the patent filings are related to the Industrial Internet of Things, digital communications and instrument diagnostics. Under the motto #empowerthefield, in 2018 the measurement engineering specialist began to bundle its digital activities with a focus on Heartbeat Technology, as well as the recently introduced Netilion IIoT ecosystem.

Patent department in the US

Each invention undergoes a multistage internal evaluation process before submission to the patent office, usually within four months. To handle the stream of innovations, in 2016 an internal patent department was created in the US, one of the Group’s most important markets. Four specialists at the Greenwood, Indiana location are responsible for protecting the technical innovations. This team has full responsibility for handling all patent filings from the Group companies located in the US, plus up to 80 percent of the overseas filings.

Innovation spirit in the spotlight

Under the motto ‘Innovation – what makes us human’, Matthias Altendorf, CEO of the Endress+Hauser Group, as well as other members of the Executive Board, welcomed more than 300 guests to the annual Innovators’ Meeting, which was held in late March in Saint-Louis, France. Employees involved in patent filings presented their innovations during the company’s traditional get-together. Exceptional innovations were recognized with special awards.

Continue Reading

News Plant Construction, Engineering & Components

NSK Europe
New Chief Operating Officer

Published

on

On 1 February 2019, Dr Ulrich Nass assumed the position of Chief Operating Officer at NSK Europe. The appointment reflects the company’s ambition to build further on its growth trajectory in Europe, the Middle East and Africa

Bringing decades of leadership experience in technology companies, primarily in the automotive industry, Dr Ulrich Nass has a proven track record in key NSK Europe markets. Prior to joining NSK, he served at Brose Group where he was Senior Vice President of Product Group Door Modules, and before that as Managing Director of the Product Unit Closures Systems.

Until 2012, Dr Ulrich Nass worked in various senior management positions at Kiekert AG, a specialist in side door and tailgate latches for automobiles. His final position at Kiekert AG was as Executive Vice President Global Product Development and Program Management.

Dr Ulrich Nass completed a master’s degree in mechanical engineering and did his PhD on the wear of worm gears at the Ruhr-University Bochum

Continue Reading

Food & Beverage News

Agriculture business
G&G partners with Camellia GroupPicture

Published

on

Green & Gold Macadamias (G&G) and AIM listed Camellia Group Plc
Picture: Green & Gold Macadamias and AIM listed Camellia Group Plc

Green & Gold Macadamias (G&G) and AIM listed Camellia Group Plc announced their strategic macadamia marketing partnership. This adds to G&G’s extensive processor and producer partner network in key growing territories including Australia, South Africa, Kenya, Malawi and Brazil. Both organisations take a long view of the macadamia market: continued growth in supply, together with changing consumer demands, means planning for the future central to philosophy.

“We are delighted that Camellia has taken the decision to market their macadamia brand, Maclands through G&G. The addition of their produce now makes us responsible for selling 20% of the globe’s kernel crop in all markets around the world. Quality predicates who we do business with, and Camellia represents a trusted partner in this regard. Guaranteed increase in quality supply creates the opportunity to scale vertically into new product markets and horizontally into new geographies.”

Brian Loader, CEO, G&G

A unique aspect to this sector is the parallel rise of both supply and demand for product. Consumer trends around plant based and healthy eating are growing: and they are here to stay. Additionally, today’s customer is discerning and sensitive to sustainable, ethical and traceable food production. Global supply of macadamias has increased over 50% in the last 5 years to 210,000 tonnes in-shell. According to the International Nut Council, the crop is projected to double again by 2023. G&G’s focus is to innovate in how and where this future supply is absorbed into market.

Macadamias, currently predominantly consumed as a snack, hold a premium perception. Prospectively G&G is carving the way for new products in a variety of sweet and savoury foods like butters, milks, cheese and yoghurts to biscuits and ice cream, amongst others. Unilever’s Magnum ice cream brand has recently launched a macadamia ice cream in Australia, Indonesia and Thailand, using G&G’s macadamias. Investment into infrastructure to support these future market changes is ongoing. The nut’s oil is also of interest to the food, cosmetic and health industry.

“G&G is specialist in what they do: a highly professional macadamia marketing company with a large network of reputable producers and an established, strategic customer base, in a variety of segments around the globe. The organisation also has cultivated longstanding direct relationships key customers and leading retailers. This market diversification, together with our aligned vision for value add and vertical integration, places G&G in a strong marketing position for years to come. This partnership allows us to be well placed to market our growth in product over the next ten years.” says Graham Mclean, Managing Director of Agriculture, Camellia.

Camellia has long-standing macadamia operations that started in Malawi in the 1980’s. Over the years the Group has invested in orchard growth and processing infrastructure. Its reach extends, in varying stages of maturity, across 1400 hectares in Malawi, 1100 hectares in South Africa and currently 1000 hectares in Kenya, with plans to increase Kenyan orchards to 1500 hectares over the next ten years. This makes Camellia one of the world’s largest macadamia producers.

Continue Reading